<DOC>
	<DOCNO>NCT00722488</DOCNO>
	<brief_summary>This open-label , multicenter , phase 1 , dose escalation study MLN4924 adult patient lymphoma multiple myeloma . The patient population consist adult confirm diagnosis lymphoma ( Waldenstrom 's macroglobulinemia permit ) multiple myeloma relapse and/or refractory least 2 prior standard chemotherapeutic regimen curative option exists . Patients expansion cohort , Schedule E , must specifically Hodgkin lymphoma , DLBCL-GCB subtype , DLBCL-non-GCB subtype , Mantle Cell Lymphoma ( MCL ) . Patients multiple myeloma longer evaluated part study .</brief_summary>
	<brief_title>Study MLN4924 , Novel Inhibitor Nedd8 Activating Enzyme , Adult Patients With Lymphoma Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<criteria>Eastern Cooperative Oncology Group ( ECOG ) performance status 02 . Patients must confirm diagnosis lymphoma ( Waldenstrom 's macroglobulinemia permit ) multiple myeloma relapse and/or refractory least 2 prior standard chemotherapeutic regimen curative option exists . 1 . As Protocol Amendment 7 , patient expansion cohort , Schedule E , must specifically Hodgkin lymphoma , DLBCLGCB subtype , DLBCLnonGCB subtype , Mantle Cell Lymphoma ( MCL ) . Patients multiple myeloma longer evaluated part study . Tumor evaluable radiography , serum urine electrophoresis ( patient multiple myeloma ) , clinical evaluation . 1 . As Protocol Amendment 7 , tumor evaluable radiography clinical evaluation . Suitable venous access conduct blood sample MLN4924 Adequate Organ Function Systemic antineoplastic therapy within 21 day precede first dose study treatment , rituximab therapy within 2 month precede first dose study treatment ( unless evidence PD since last dose rituximab ) . Treatment corticosteroid within 7 day precede first dose study treatment . Prior treatment radiation therapy involve &gt; 25 % bone marrow ; Any radiotherapy within 14 day first dose study treatment . Treatment CYP3A inducer within 14 day first dose MLN4924 . Moderate strong CYP3A inhibitor CYP3A inducer permit study . Patients require Coumadin switch low molecular weight heparin consider study . Absolute neutrophil count le 1,000/mm3 ; platelet count less 75,000/mm3 . Calculated creatinine clearance less equal 50 mL/minute .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>